How benzodiazepines work and why their side-effect profile is a problem
Benzodiazepines (diazepam, lorazepam, alprazolam, and their relatives) achieve anxiolysis through a well-characterised mechanism: positive allosteric modulation of GABA-A receptors. By binding to a site distinct from the receptor's primary GABA binding site, they increase the frequency of chloride ion channel opening when GABA is present, amplifying inhibitory neurotransmission throughout the brain.
The result is effective anxiolysis, but at a cost that has been recognised in clinical psychiatry for decades. GABA-A receptors are distributed widely across the nervous system, not just in regions relevant to anxiety circuitry. Global enhancement of GABA-A sensitivity therefore produces sedation, motor coordination impairment, anterograde amnesia, and respiratory depression at higher doses. These effects are inseparable from the mechanism rather than merely incidental to a specific compound.
More damaging still is the dependence liability. Sustained GABA-A upregulation triggers compensatory downregulation of GABA receptors and upregulation of excitatory glutamate signalling. When the benzodiazepine is withdrawn, this compensatory shift leaves the nervous system in a hyperexcitable state that produces rebound anxiety exceeding baseline levels, sometimes with seizure risk. This pharmacological trap has made benzodiazepines among the most problematic prescription drugs in terms of long-term management, and has motivated decades of searching for alternatives.
The enkephalin system — Selank's alternative anxiolytic route
Selank's designers at the Institute of Molecular Genetics in Moscow took a fundamentally different approach. Rather than amplifying inhibitory neurotransmission directly, they targeted the endogenous opioid peptide system, specifically the enkephalins, which are released constitutively in regions including the amygdala, the periaqueductal grey, and the prefrontal cortex, and which are known to modulate anxiety and stress responses.
Selank is built on tuftsin, a naturally occurring tetrapeptide with immunomodulatory properties, extended with a stabilising proline-glycine-proline tail. Its primary anxiolytic mechanism is inhibition of enkephalinase, the enzyme responsible for degrading enkephalins after their release. By slowing enkephalin breakdown, Selank extends the active life of the brain's endogenous anxiety-modulating peptides without introducing an exogenous opioid agonist. The result is elevated enkephalin tone in relevant circuits, with anxiolytic effects that arise from the nervous system's own biochemistry rather than from direct receptor manipulation.
This distinction matters for the side-effect prediction. Enkephalin receptors are distributed differently from GABA-A receptors, with lower expression in the motor circuits and memory-encoding regions where benzodiazepines cause the most collateral disruption. And because Selank raises endogenous peptide levels rather than forcing a receptor into an unnatural state, the compensatory adaptations that drive benzodiazepine dependence have less reason to occur.
What the Selank vs benzodiazepine comparative trials measured
The published comparative trial literature comparing Selank against benzodiazepine comparators is primarily Russian in origin, with the most frequently cited work emerging from the 2000s. The study designs typically enrolled patients with generalised anxiety disorder or anxiety-neurotic conditions as defined by Russian diagnostic frameworks, administered Selank intranasally against a benzodiazepine control, and measured outcomes on standardised anxiety rating scales alongside cognitive assessments.
The most rigorous version of this work used observer-rated anxiety scales alongside self-report measures, ran for several weeks, and included follow-up assessments after discontinuation. These methodological elements were genuinely thoughtful choices that give the resulting data more interpretive weight than a simple placebo-controlled design would: multi-rater assessment, an active comparator rather than placebo only, and post-discontinuation follow-up.
Anxiolytic effect size: how do the outcomes compare?
On primary anxiety outcome measures, the published trials reported comparable reductions in anxiety scores between Selank and the benzodiazepine comparator by the end of the treatment period. The mean score reductions achieved statistical significance in both arms, and the between-group differences did not reach significance, meaning the trial failed to detect a difference in anxiolytic efficacy between the two approaches.
This is a meaningful finding, but it needs careful interpretation. The trials were likely underpowered to detect small but clinically meaningful differences in efficacy, and the benzodiazepine comparators used were sometimes lower doses than might be prescribed for severe anxiety in clinical practice. The conclusion that Selank "works as well as benzodiazepines" should be read as "we failed to detect a significant efficacy difference in these populations at these doses," a useful starting point, but not the last word.
Cognitive effects: amnesia vs clarity
The divergence between the two approaches was most apparent on cognitive assessments. Benzodiazepine-treated subjects showed the expected pattern of anterograde amnesia and slowed processing speed, measurable on standard neuropsychological tests and consistent with the known effects of GABA-A upregulation on encoding and retrieval. Selank-treated subjects in the same trials showed no such decrement, and in some assessments showed modest improvements on measures of sustained attention and mental clarity.
This cognitive profile difference is arguably more important clinically than the primary anxiety comparison. An anxiolytic that does not degrade the cognitive function it is partly intended to protect is pharmacologically superior, all else being equal, and the cognitive data provides a mechanistically plausible explanation for why: the enkephalinase route does not touch the receptor systems responsible for benzodiazepine-induced amnesia.
The sedation differential — why it matters for daytime function
Sedation is the complaint that drives most anxious patients to resist benzodiazepine treatment, and it is the limitation that most often forces dose reductions in clinical practice. A compound that produces equivalent anxiolysis without sedation does not merely avoid an inconvenience. It changes the functional calculus of treatment entirely.
In the comparative trials, sedation was rated by both subjects and assessors. Benzodiazepine recipients reported sedation at rates consistent with the known profile of the comparator compounds. Selank recipients reported notably lower sedation scores, and motor coordination assessments showed no significant impairment. This difference persisted across the treatment period rather than attenuating as a tolerance effect might produce.
The implication for research design is significant. Sedation in a trial subject is a confounding variable: it affects performance on cognitive tasks, changes reactivity in behavioural paradigms, and complicates the interpretation of anxiety-reduction data. An anxiolytic that achieves comparable anxiolysis without sedation produces cleaner research data as well as a more tolerable experimental experience for subjects.
What the Russian approval means — and what it doesn't say about Western populations
Selank received regulatory approval for clinical use in the Russian Federation for anxiety and asthenic disorders, a genuine milestone that distinguishes it from the purely preclinical compounds that populate most of the nootropic peptide field. That approval was based on the accumulated Russian trial data, reviewed by Russian regulatory authorities operating under Russian standards. It is meaningful evidence of a real therapeutic effect, not marketing copy.
What it does not provide is a fully characterised safety and efficacy profile applicable to Western populations with Western diagnostic frameworks and Western prescribing standards. The trials were conducted in Russian populations, the diagnostic categories used partially diverge from DSM or ICD criteria, and independent replication of the key comparative findings outside Russia remains limited. The published Selank–benzodiazepine comparative trial breakdown provides the most complete account of what the data actually shows for those who want to engage with the primary findings in detail. The honest position is that the evidence supports cautious optimism rather than either dismissal or uncritical endorsement.
